A new therapy schedule for pediatric non‐Hodgkin lymphoma toxicity and preliminary results

A. T. Meadows, R. D.T. Jenkin, J. Anderson, R. Chilcote, Peter Felix Coccia, P. Exelby, J. Kushner, S. Leikin, S. Siegel, J. F. Wilson, D. Hammond

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

A pilot study of the toxicity and efficacy of a new treatment schedule for childhood non‐Hodgkin's lymphoma was conducted by members of the Children's Cancer Study Group (CCSG) prior to its use in a randomized phase III trial. Chemotherapeutic agents used were cyclophosphamide (CPM), vincristine (VCR), and prednisone, together with intravenous (IV) and intrathecal methotrexate (IT MTX). Radiation therapy was also employed. From September 1976 to April 1977, 27 eligible, newly diagnosed patients with non‐Hodgkin's lymphoma were entered onto this pilot study. Toxicity was acceptable with minor adjustments in dosage and timing of the myelosuppressive agents. Fourteen of the 22 patients entered onto maintenance remain entirely disease‐free, and all have completed the prescribed course of chemotherapy. None of the 12 patients characterized as having a “favorable” prognosis has relapsed, with a median follow‐up of 27 months from on study.

Original languageEnglish (US)
Pages (from-to)15-24
Number of pages10
JournalMedical and Pediatric Oncology
Volume8
Issue number1
DOIs
StatePublished - Jan 1 1980

Fingerprint

Non-Hodgkin's Lymphoma
Appointments and Schedules
Pediatrics
Vincristine
Prednisone
Methotrexate
Cyclophosphamide
Radiotherapy
Therapeutics
Maintenance
Drug Therapy
Neoplasms

Keywords

  • multidisciplinary therapy (COMP)
  • non‐Hodgkin's lymphoma
  • staging
  • survival

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Meadows, A. T., Jenkin, R. D. T., Anderson, J., Chilcote, R., Coccia, P. F., Exelby, P., ... Hammond, D. (1980). A new therapy schedule for pediatric non‐Hodgkin lymphoma toxicity and preliminary results. Medical and Pediatric Oncology, 8(1), 15-24. https://doi.org/10.1002/mpo.2950080104

A new therapy schedule for pediatric non‐Hodgkin lymphoma toxicity and preliminary results. / Meadows, A. T.; Jenkin, R. D.T.; Anderson, J.; Chilcote, R.; Coccia, Peter Felix; Exelby, P.; Kushner, J.; Leikin, S.; Siegel, S.; Wilson, J. F.; Hammond, D.

In: Medical and Pediatric Oncology, Vol. 8, No. 1, 01.01.1980, p. 15-24.

Research output: Contribution to journalArticle

Meadows, AT, Jenkin, RDT, Anderson, J, Chilcote, R, Coccia, PF, Exelby, P, Kushner, J, Leikin, S, Siegel, S, Wilson, JF & Hammond, D 1980, 'A new therapy schedule for pediatric non‐Hodgkin lymphoma toxicity and preliminary results', Medical and Pediatric Oncology, vol. 8, no. 1, pp. 15-24. https://doi.org/10.1002/mpo.2950080104
Meadows, A. T. ; Jenkin, R. D.T. ; Anderson, J. ; Chilcote, R. ; Coccia, Peter Felix ; Exelby, P. ; Kushner, J. ; Leikin, S. ; Siegel, S. ; Wilson, J. F. ; Hammond, D. / A new therapy schedule for pediatric non‐Hodgkin lymphoma toxicity and preliminary results. In: Medical and Pediatric Oncology. 1980 ; Vol. 8, No. 1. pp. 15-24.
@article{88ce133576254ab2b25e8470a0a8ad72,
title = "A new therapy schedule for pediatric non‐Hodgkin lymphoma toxicity and preliminary results",
abstract = "A pilot study of the toxicity and efficacy of a new treatment schedule for childhood non‐Hodgkin's lymphoma was conducted by members of the Children's Cancer Study Group (CCSG) prior to its use in a randomized phase III trial. Chemotherapeutic agents used were cyclophosphamide (CPM), vincristine (VCR), and prednisone, together with intravenous (IV) and intrathecal methotrexate (IT MTX). Radiation therapy was also employed. From September 1976 to April 1977, 27 eligible, newly diagnosed patients with non‐Hodgkin's lymphoma were entered onto this pilot study. Toxicity was acceptable with minor adjustments in dosage and timing of the myelosuppressive agents. Fourteen of the 22 patients entered onto maintenance remain entirely disease‐free, and all have completed the prescribed course of chemotherapy. None of the 12 patients characterized as having a “favorable” prognosis has relapsed, with a median follow‐up of 27 months from on study.",
keywords = "multidisciplinary therapy (COMP), non‐Hodgkin's lymphoma, staging, survival",
author = "Meadows, {A. T.} and Jenkin, {R. D.T.} and J. Anderson and R. Chilcote and Coccia, {Peter Felix} and P. Exelby and J. Kushner and S. Leikin and S. Siegel and Wilson, {J. F.} and D. Hammond",
year = "1980",
month = "1",
day = "1",
doi = "10.1002/mpo.2950080104",
language = "English (US)",
volume = "8",
pages = "15--24",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - A new therapy schedule for pediatric non‐Hodgkin lymphoma toxicity and preliminary results

AU - Meadows, A. T.

AU - Jenkin, R. D.T.

AU - Anderson, J.

AU - Chilcote, R.

AU - Coccia, Peter Felix

AU - Exelby, P.

AU - Kushner, J.

AU - Leikin, S.

AU - Siegel, S.

AU - Wilson, J. F.

AU - Hammond, D.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - A pilot study of the toxicity and efficacy of a new treatment schedule for childhood non‐Hodgkin's lymphoma was conducted by members of the Children's Cancer Study Group (CCSG) prior to its use in a randomized phase III trial. Chemotherapeutic agents used were cyclophosphamide (CPM), vincristine (VCR), and prednisone, together with intravenous (IV) and intrathecal methotrexate (IT MTX). Radiation therapy was also employed. From September 1976 to April 1977, 27 eligible, newly diagnosed patients with non‐Hodgkin's lymphoma were entered onto this pilot study. Toxicity was acceptable with minor adjustments in dosage and timing of the myelosuppressive agents. Fourteen of the 22 patients entered onto maintenance remain entirely disease‐free, and all have completed the prescribed course of chemotherapy. None of the 12 patients characterized as having a “favorable” prognosis has relapsed, with a median follow‐up of 27 months from on study.

AB - A pilot study of the toxicity and efficacy of a new treatment schedule for childhood non‐Hodgkin's lymphoma was conducted by members of the Children's Cancer Study Group (CCSG) prior to its use in a randomized phase III trial. Chemotherapeutic agents used were cyclophosphamide (CPM), vincristine (VCR), and prednisone, together with intravenous (IV) and intrathecal methotrexate (IT MTX). Radiation therapy was also employed. From September 1976 to April 1977, 27 eligible, newly diagnosed patients with non‐Hodgkin's lymphoma were entered onto this pilot study. Toxicity was acceptable with minor adjustments in dosage and timing of the myelosuppressive agents. Fourteen of the 22 patients entered onto maintenance remain entirely disease‐free, and all have completed the prescribed course of chemotherapy. None of the 12 patients characterized as having a “favorable” prognosis has relapsed, with a median follow‐up of 27 months from on study.

KW - multidisciplinary therapy (COMP)

KW - non‐Hodgkin's lymphoma

KW - staging

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=0018884655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018884655&partnerID=8YFLogxK

U2 - 10.1002/mpo.2950080104

DO - 10.1002/mpo.2950080104

M3 - Article

VL - 8

SP - 15

EP - 24

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -